Geron (GERN) Equity Income (2010 - 2011)
Geron's (GERN) quarterly Equity Income came in at -$168000.0 in Q2 2011, up 66.13% year-over-year from -$101126.2 in Q2 2010, and up 49.85% quarter-over-quarter from -$335000.0 in Q1 2011.
Powered by 
Analysis
Geron (GERN) Equity Income (2010 - 2011) Analysis & Trends
Geron has disclosed Equity Income across 2 years of filings, most recently posting -$168000.0 for Q2 2011.
- In Q2 2011, Equity Income rose 66.13% year-over-year to -$168000.0; the TTM figure through Mar 2012 stood at -$168000.0 (up 92.65% YoY), while the FY2011 annual figure was -$503000.0, up 78.57% from the prior year.
- Equity Income came in at -$168000.0 for Q2 2011 at Geron, up from -$335000.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$168000.0 in Q2 2011 to a low of -$1.2 million in Q4 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2011 | -168,000.00 |
| Mar 31, 2011 | -335,000.00 |
| Dec 31, 2010 | -1.21 Mn |
| Sep 30, 2010 | -243,000.00 |
| Jun 30, 2010 | -496,000.00 |